 This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the efficacy and safety of rivaroxaban as compared to acetylsalicylic acid in reducing stroke, transient ischemic attack TIA and neurocognitive decline, in subjects with non-valvular AF and with low risk of stroke. 